loading...

Autosomal Dominant Polycystic Kidney Disease Pain and Discomfort Scale (ADPKD-PDS)

Otsuka Pharmaceutical Development & Commercialization, Inc (USA)

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Developed in 2013 - version 6 currently available

A separate instrument for use in adolescent subjects is under development

Authors

Otsuka Pharmaceutical Development & Commercialization, Inc (USA)

Copyright
ADPKD-PDS © Otsuka Pharmaceutical Development & Commercialization, Inc. 2013, All Rights Reserved.
Objective
To understand the disease-specific burden of pain and discomfort due to ADPKD
Therapeutic area
  • Female Urogenital Diseases and Pregnancy Complications
  • Male Urogenital Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Polycystic Kidney, Autosomal Dominant For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Cole JC, Krasa HB, Cheng R, et al. The Impact of Autosomal Dominant Polycystic Kidney Disease (ADPKD) on Patients' Health-Related Quality of Life (HRQoL): Developed of a Conceptual Framework. In: 16th International Society of Pharmacoeconomics and Outcomes Research (ISPOR); May 21-25, 2011; Baltimore, USA. Value in Health. 2011 May;14(3):A77 (Poster Abstract)

Cole JC, Oberdhan D, Cheng R, et al. Patient-Experienced Impact from Autosomal Dominant Polycystic Kidney Disease (ADPKD): Summary of Burden Noted in North American, European, and Japanese Focus Groups. In: 48th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; June 23-26, 2011; Prague (Poster Abstract)

Oberdhan D, Chapman AB, Davison SN, et al. Patient-reported Pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD): Initial Concepts Based on Patient Focus Group Discussions. American Society of Nephrology - Kidney Week. 2013;SA-PO283:692A (Poster Abstract)

Cheng R, Oberdhan D, Krasa H, Cole JC. Patient-reported Pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD): Concept Stability Between Europe and United States (US) Focus Groups. ISOQOL 2013. Poster.

Palsgrove AC, Guay-Woodford LM, Cheng R, et al. Burden of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Effects on the Daily Lives of Patients and Their Caregivers. American Journal of Kidney Diseases. 2014 May;63(5):B86 (Poster Abstract)

Oberdhan D, Palsgrove A, Cole J, Blais J, Cheng R. Patient Experience with Pain Related to Autosomal Dominant Polycystic Kidney Disease (ADPKD). World Congress of Nephrology, 2015

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

Otsuka Pharmaceutical Development & Commercialization, Inc (USA)

Otsuka Pharmaceutical Development & Commercialization, Inc.
2440 Research Boulevard
Rockville, MD 20850
USA
Phone: +1-240-683-3517 |
Fax: +1-301-721-7517 |

Contact person:
Dorothee Oberdhan, MS
Senior Manager, HEOR and Outcomes Management
E-mail: dorothee.oberdhan@otsuka-us.com

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Non-Commercial Users

You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.

Commercial Users

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. In order to accelerate the process, you may attach the User Agreement (even if not finalized) to your online request. 
  4. Our PROVIDE team will get back to you with the needed information in a timely manner

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

ADPKD-PDS

Chinese for Taiwan
Czech for Czech Republic
Dutch for Belgium (Flemish)
Dutch for the Netherlands
English for Australia
English for the UK
French for Belgium
French for Canada
French for France
French for Switzerland
German for Germany
German for Switzerland
Hungarian for Hungary
Italian for Italy
Italian for Switzerland
Japanese for Japan
Korean for Korea
Mandarin for China
Polish for Poland
Portuguese for Brazil
Romanian for Romania
Russian for Russia
Spanish for Argentina
Spanish for Spain
Spanish for the USA
Turkish for Turkey

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

E-versions

Conditions to implement in electronic applications

Please refer to the "Contact and conditions of use" tab

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us